Zai Lab Limited, a biopharmaceutical company listed on the Hong Kong Stock Exchange and NASDAQ, has announced the grant of Restricted Share Units under its 2024 Equity Incentive Plan. On May 12, 2025, U.S. Eastern Time, the company awarded 9,800 American Depositary Shares (ADSs) to two grantees. Following this allocation, 82,686,733 shares remain available for future grants under the plan. This move is part of the company's ongoing efforts to align with its equity compensation strategy, as approved during the 2024 annual general meeting of shareholders.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.